Table 1.
AJCC 7th ed TNM stage | TN combinations | Patients (n) | TN score | 5-yr OS | Proposed TNM stage | TN combinations | Patients (n) | TN score | 5-yr OS |
I | T1N0 | 10930 | 0.58 | 78.7% | I | T1N0 | 10930 | 0.58 | 78.7% |
T2N0 | 12931 | 1.16 | 74.3% | T1N1a | 643 | 1.00 | 76.7% | ||
IIa | T3N0 | 40338 | 1.74 | 66.7% | II | T2N0 | 12931 | 1.16 | 74.3% |
IIb | T4aN0 | 5020 | 2.32 | 60.6% | T1N1b | 325 | 1.42 | 65.8% | |
IIc | T4bN0 | 3088 | 2.90 | 45.7% | T2N1a | 1270 | 1.58 | 72.1% | |
IIIa | T1N1a | 643 | 1.00 | 76.7% | T3N0 | 40338 | 1.74 | 66.7% | |
T2N1a | 1270 | 1.58 | 72.1% | T1N2a | 77 | 1.84 | 57.4% | ||
T1N1b | 325 | 1.42 | 65.8% | T2N1b | 896 | 2.00 | 67.7% | ||
T2N1b | 896 | 2.00 | 67.7% | IIIa | T3N1a | 8759 | 2.16 | 58.2% | |
T1N2a | 77 | 1.84 | 57.4% | T1N2b | 27 | 2.26 | 55.0% | ||
IIIb | T2N2a | 300 | 2.41 | 66.6% | T4aN0 | 5020 | 2.32 | 60.6% | |
T3N1a | 8759 | 2.16 | 58.2% | T2N2a | 300 | 2.41 | 66.6% | ||
T4aN1a | 1311 | 2.74 | 52.2% | T3N1b | 9107 | 2.58 | 51.7% | ||
T3N1b | 9107 | 2.58 | 51.7% | T4aN1a | 1311 | 2.74 | 52.2% | ||
T1N2b | 27 | 2.26 | 55.0% | T2N2b | 95 | 2.84 | 51.0% | ||
T2N2b | 95 | 2.84 | 51.0% | T4bN0 | 3088 | 2.90 | 45.7% | ||
T4aN1b | 1460 | 3.16 | 42.1% | T3N2a | 5331 | 3.00 | 42.8% | ||
T3N2a | 5331 | 3.00 | 42.8% | IIIb | T4aN1b | 1460 | 3.16 | 42.1% | |
IIIc | T4aN2a | 982 | 3.58 | 32.5% | T4bN1a | 845 | 3.32 | 30.6% | |
T3N2b | 3235 | 3.42 | 30.4% | T3N2b | 3235 | 3.42 | 30.4% | ||
T4bN1a | 845 | 3.32 | 30.6% | T4aN2a | 982 | 3.58 | 32.5% | ||
T4bN1b | 929 | 3.74 | 25.4% | T4bN1b | 929 | 3.74 | 25.4% | ||
T4bN2a | 730 | 4.16 | 18.3% | T4aN2b | 671 | 4.00 | 17.5% | ||
T4aN2b | 671 | 4.00 | 17.5% | IIIc | T4bN2a | 730 | 4.16 | 18.3% | |
T4bN2b | 653 | 4.58 | 12.9% | T4bN2b | 653 | 4.58 | 12.9% |
OS: Observed survival. AJCC: American Joint Committee on Cancer; TNM: Tumor node metastasis.